Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Oguchi T, Kanayama Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Shioura T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N. Hattori Y, et al. Mod Rheumatol. 2018 Jan;28(1):119-125. doi: 10.1080/14397595.2017.1317320. Epub 2017 May 2. Mod Rheumatol. 2018. PMID: 28463029
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients.
Takahashi N, Kojima T, Terabe K, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Yoshioka Y, Ishiguro N. Takahashi N, et al. Among authors: hattori y. Mod Rheumatol. 2013 Sep;23(5):904-12. doi: 10.1007/s10165-012-0760-4. Epub 2012 Sep 14. Mod Rheumatol. 2013. PMID: 22975734
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N. Kojima T, et al. Among authors: hattori y. Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26. Mod Rheumatol. 2013. PMID: 23099471
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kanayama Y, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Terabe K, Yoshioka Y, Ishiguro N. Takahashi N, et al. Among authors: hattori y. Clin Rheumatol. 2014 Jan;33(1):39-47. doi: 10.1007/s10067-013-2392-2. Epub 2013 Sep 22. Clin Rheumatol. 2014. PMID: 24057092 Free PMC article.
Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Terabe K, Yabe Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Kanayama Y, Oguchi T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N. Hattori Y, et al. J Rheumatol. 2016 Aug;43(8):1475-9. doi: 10.3899/jrheum.151006. Epub 2016 Jun 15. J Rheumatol. 2016. PMID: 27307531
2,144 results